secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2023-12-27T23:59:59+00:00
Accession:  0000950170-23-073144
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics announces positive Phase 3 SEQUOIA-HCM results for aficamten in obstructive HCM
--------------------------------------------------------------------------------

- Aficamten improved exercise capacity (pVO2) vs placebo: LS mean diff 1.74 mL/kg/min (p=0.000002).
- All 10 prespecified secondary endpoints met with statistical significance (p<0.0001), including KCCQ-CSS and NYHA class.
- Safety profile comparable to placebo; SAEs 5.6% aficamten vs 9.3% placebo; LVEF <50% in 3.5% vs 0.7%.
- No worsening heart failure or treatment interruptions due to low LVEF; full results at upcoming medical conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017023073144/0000950170-23-073144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017023073144/cytk-20231227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-073144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer